首页> 外文期刊>Bone marrow transplantation >Potential protective effect of Helicobacter pylori on the development of gastrointestinal GvHD
【24h】

Potential protective effect of Helicobacter pylori on the development of gastrointestinal GvHD

机译:幽门螺杆菌对胃肠道GvHD发育的潜在保护作用

获取原文
获取原文并翻译 | 示例
       

摘要

Previous reports ascribe a modulating capacity of the immune response to Helicobacter pylori (HP). Our hypothesis was to demonstrate in a prospective study that HP infection could have a protective effect against development of gastrointestinal GvHD in patients receiving allogeneic hematopoietic cell transplantation (HCT). Presence of HP before transplant was determined using C-13 urea breath test. Seventy-nine patients receiving an allogeneic HCT were included and 93.7% of them received PBSC; in 51.9%, the donor was unrelated. Acute gastrointestinal GvHD was diagnosed in 51.9% (n = 41). In the multivariable analysis, HP infection was associated with a lower frequency of gastrointestinal GvHD (odds ratio (OR) = 0.19 (95% confidence interval (CI): 0.05-0.67); in contrast, an unrelated donor was associated with a higher frequency of gastrointestinal GvHD (odds ratio = 5.4 (95% confidence interval: 1.6-18.2). One year overall survival (OS) was 74%. In the multivariate Cox proportional-hazards regression analysis, stages 0-II gastrointestinal GvHD (hazards ratio (HR) = 0.19), reduced intensity conditioning (HR = 0.04) and tacrolimus-sirolimus GvHD prophylaxis (HR = 0.06) were all associated with a better OS. In summary, HP infection could have a role in decreasing gastrointestinal GvHD in patients receiving allogeneic HCT from peripheral blood including related and unrelated donors.
机译:先前的报道归因于对幽门螺杆菌(HP)的免疫应答的调节能力。我们的假设是在一项前瞻性研究中证明,在接受异基因造血细胞移植(HCT)的患者中,HP感染可能对胃肠道GvHD的发生具有保护作用。使用C-13尿素呼气试验确定移植前是否存在HP。纳入了接受异基因HCT的79例患者,其中93.7%的患者接受了PBSC。在51.9%的捐赠者中没有亲戚关系。急性胃肠道GvHD诊断率为51.9%(n = 41)。在多变量分析中,HP感染与胃肠道GvHD发生频率较低相关(比值比(OR)= 0.19(95%置信区间(CI):0.05-0.67));相反,无关的供体与较高频率相关胃肠道GvHD的风险比(比值= 5.4(95%置信区间:1.6-18.2)。一年总生存(OS)为74%。在多因素Cox比例风险回归分析中,胃肠道GvHD的0-II期(风险比( HR)= 0.19),强度降低(HR = 0.04)和他克莫司-西罗莫司GvHD预防(HR = 0.06)均与OS改善相关。总的来说,HP感染可能在异基因患者中降低胃肠道GvHD来自包括相关和不相关供体的外周血的HCT。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号